ECS Botanics Surpasses 60% B2C Revenue with New Sugar-Free Gummies

B2C Sales Momentum Accelerates

ECS Botanics Holdings Ltd (ASX, ECS) has marked a significant shift in its revenue mix, with direct-to-consumer (B2C) sales accounting for 62% of total revenue in October 2025. This surpasses the previous quarter's 53%, underscoring the company’s successful strategic pivot towards growing its branded sales through pharmacies and distributors. The milestone reflects ECS's commitment to building brand equity and meeting patient needs through innovative product offerings.

Introducing OzSun Sugar-Free Gummies

This momentum is further supported by the launch of the OzSun 25mg THC pastilles, a sugar-free and vegan gummy product now available nationwide. Positioned as an affordable and differentiated option in a crowded gummies market, these pastilles cater to consumers seeking healthier alternatives without compromising on efficacy. ECS plans to expand this range with two additional sugar-free pastilles featuring combined THC and CBD formulations within the next six weeks, aiming to capture a broader segment of the medicinal cannabis market.

Expanding Distribution Through Strategic Partnership

Complementing product innovation, ECS has entered a national distribution partnership with Burleigh Heads Cannabis, a subsidiary of ASX-listed Vitura Health Limited. This alliance facilitates the listing of ECS products on Canview, one of Australia's leading medical cannabis platforms. Leveraging Vitura's extensive pharmacy and clinic networks, ECS is poised to significantly enhance patient access and accelerate B2C growth across the country.

Looking Ahead, Growth and International Expansion

While the initial revenue contribution from the new gummies is expected to be moderate, the product launch strategically fills a niche in the Australian market and strengthens the OzSun brand portfolio. ECS is also actively progressing towards launching its brands in Germany, signaling ambitions beyond domestic growth. The company remains focused on disciplined operations, product innovation, and brand development to sustain its upward trajectory.

Managing Director Nan-Maree Schoerie highlighted the company’s confidence in its scalable B2C model, emphasizing the combined impact of product launches and partnerships in driving shareholder and patient value.